Phase 3 trial in 61 adults with drug-resistant epilepsy after failed VNS: anterior thalamic DBS vs best medical treatment gave a non-significant difference in median 12-month severe seizure change (-44% vs -6%; p=.09). No major DBS-related adverse events.
RCTn = 61
Chabardès et al. Deep brain stimulation of the thalamus for intractable epilepsy (FRANCE study): A randomized clinical trial